Baird Maintains Underperform on Vertex Pharmaceuticals, Raises Price Target to $350

Benzinga Newsdesk www.benzinga.com Negative 60.2%

Neg 60.2% Neu 0% Pos 0%

Baird analyst Brian Skorney maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Underperform and raises the price target from $330 to $350.